Gibell: Net profit in 2025 was 259 million yuan, a year-on-year increase of 17.94%.

Jibei releases its performance report, achieving a total operating income of 965 million yuan in 2025, a year-on-year growth of 7.63%; net profit of 259 million yuan, a year-on-year growth of 17.94%. During the reporting period, the overall business operations of the company were good. On one hand, it continued to strengthen team building and market development, resulting in growth in total revenue and net profit attributable to the parent company owner, with sales revenue of the main product Niquinol maintaining a fast growth trend; on the other hand, it actively promoted the research and development progress of new drugs such as antidepressant drug JJH201501 and anti-tumor drug JJH201601, successfully completing Phase III clinical trials of antidepressant drug JJH201501 in an orderly manner, and progressing smoothly with Phase IIa clinical trials of anti-tumor drug JJH201601.